1281 related articles for article (PubMed ID: 30231922)
1. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
2. Resolvin D1 prevents epithelial-mesenchymal transition and reduces the stemness features of hepatocellular carcinoma by inhibiting paracrine of cancer-associated fibroblast-derived COMP.
Sun L; Wang Y; Wang L; Yao B; Chen T; Li Q; Liu Z; Liu R; Niu Y; Song T; Liu Q; Tu K
J Exp Clin Cancer Res; 2019 Apr; 38(1):170. PubMed ID: 30999932
[TBL] [Abstract][Full Text] [Related]
3. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Wang Z; Qu L; Deng B; Sun X; Wu S; Liao J; Fan J; Peng Z
Sci Rep; 2016 Sep; 6():33205. PubMed ID: 27628214
[TBL] [Abstract][Full Text] [Related]
4. COMP promotes pancreatic fibrosis by activating pancreatic stellate cells through CD36-ERK/AKT signaling pathways.
Wang Y; Li HT; Liu G; Jiang CS; Ni YH; Zeng JH; Lin X; Wang QY; Li DZ; Wang W; Zeng XP
Cell Signal; 2024 Jun; 118():111135. PubMed ID: 38479555
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.
Xu Q; Liu X; Liu Z; Zhou Z; Wang Y; Tu J; Li L; Bao H; Yang L; Tu K
Mol Cancer; 2017 Jun; 16(1):103. PubMed ID: 28606154
[TBL] [Abstract][Full Text] [Related]
6. LINC00707 promotes hepatocellular carcinoma progression through activating ERK/JNK/AKT pathway signaling pathway.
Wang J; Luo Z; Yao T; Li W; Pu J
J Cell Physiol; 2019 May; 234(5):6908-6916. PubMed ID: 30317590
[TBL] [Abstract][Full Text] [Related]
7. ERK pathway activation contributes to the tumor-promoting effects of hepatic stellate cells in hepatocellular carcinoma.
Xie YX; Liao R; Pan L; Du CY
Immunol Lett; 2017 Aug; 188():116-123. PubMed ID: 28668554
[TBL] [Abstract][Full Text] [Related]
8. The herbal compound Songyou Yin (SYY) inhibits hepatocellular carcinoma growth and improves survival in models of chronic fibrosis via paracrine inhibition of activated hepatic stellate cells.
Bu Y; Jia QA; Ren ZG; Xue TC; Zhang QB; Zhang KZ; Zhang QB; You Y; Tian H; Qin LX; Tang ZY
Oncotarget; 2015 Nov; 6(37):40068-80. PubMed ID: 26517671
[TBL] [Abstract][Full Text] [Related]
9. Extracellular vesicles-derived OncomiRs mediate communication between cancer cells and cancer-associated hepatic stellate cells in hepatocellular carcinoma microenvironment.
Li J; Yan Y; Ang L; Li X; Liu C; Sun B; Lin X; Peng Z; Zhang X; Zhang Q; Wu H; Zhao M; Su C
Carcinogenesis; 2020 Apr; 41(2):223-234. PubMed ID: 31140556
[TBL] [Abstract][Full Text] [Related]
10. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis.
Ma XL; Shen MN; Hu B; Wang BL; Yang WJ; Lv LH; Wang H; Zhou Y; Jin AL; Sun YF; Zhang CY; Qiu SJ; Pan BS; Zhou J; Fan J; Yang XR; Guo W
J Hematol Oncol; 2019 Apr; 12(1):37. PubMed ID: 30971294
[TBL] [Abstract][Full Text] [Related]
11. Small nucleolar RNA ACA11 promotes proliferation, migration and invasion in hepatocellular carcinoma by targeting the PI3K/AKT signaling pathway.
Wu L; Zheng J; Chen P; Liu Q; Yuan Y
Biomed Pharmacother; 2017 Jun; 90():705-712. PubMed ID: 28419966
[TBL] [Abstract][Full Text] [Related]
12. Matrix stiffness modulates hepatic stellate cell activation into tumor-promoting myofibroblasts via E2F3-dependent signaling and regulates malignant progression.
Liu Z; Mo H; Liu R; Niu Y; Chen T; Xu Q; Tu K; Yang N
Cell Death Dis; 2021 Dec; 12(12):1134. PubMed ID: 34873170
[TBL] [Abstract][Full Text] [Related]
13. miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway.
Wang R; Yu Z; Chen F; Xu H; Shen S; Chen W; Chen L; Su Q; Zhang L; Bi J; Zeng W; Li W; Huang X; Wang Q
Biomed Pharmacother; 2018 Jul; 103():1632-1642. PubMed ID: 29864952
[TBL] [Abstract][Full Text] [Related]
14. Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells.
Wu WL; Wang WY; Yao WQ; Li GD
Int J Mol Med; 2015 Dec; 36(6):1713-9. PubMed ID: 26499886
[TBL] [Abstract][Full Text] [Related]
15. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
[TBL] [Abstract][Full Text] [Related]
16. The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells.
Jiang X; Wang J; Zhang K; Tang S; Ren C; Chen Y
Med Oncol; 2015 May; 32(5):141. PubMed ID: 25805567
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts.
Zhou Y; Ren H; Dai B; Li J; Shang L; Huang J; Shi X
J Exp Clin Cancer Res; 2018 Dec; 37(1):324. PubMed ID: 30591064
[TBL] [Abstract][Full Text] [Related]
18. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition.
Huan HB; Yang DP; Wen XD; Chen XJ; Zhang L; Wu LL; Bie P; Xia F
J Exp Clin Cancer Res; 2017 Jun; 36(1):86. PubMed ID: 28646927
[TBL] [Abstract][Full Text] [Related]
19. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
20. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma.
Yu M; Xue H; Wang Y; Shen Q; Jiang Q; Zhang X; Li K; Jia M; Jia J; Xu J; Tian Y
Int J Oncol; 2017 Mar; 50(3):975-983. PubMed ID: 28098858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]